吉西他滨单药治疗老年晚期非小细胞肺癌的临床观察

Gemcitabine in Treatment of Elderly Patients with Advanced Nonsmall Cell Lung Cancer

目的探讨吉西他滨单药治疗老年晚期非小细胞肺癌的临床效果和安全性。方法选择我院从2010年1月至2012年1月收治的老年晚期非小细胞肺癌患者42例,随机分成两组,治疗组采用吉西他滨进行治疗,对照组采用特罗凯进行治疗,对两组的治疗效果和不良反应的发生情况进行对比分析。结果治疗组的治疗总有效率、临床获益率、1年后的存活率均显著高于对照组,而治疗后各种不良反应如白细胞降低、血小板减少、恶心呕吐以及肝功能异常的发生率均显著低于对照组,两组间差异具有统计学意义(P<0.05)。结论采用吉西他滨单药治疗老年晚期非小细胞肺癌的疗效及安全性均较特罗凯更高,值得在临床推广。

Objective To assess the efficacy and safety of gemcitabine alone in treatment of elderly patients with ad-vanced non-small cell lung cancer. Methods Between January 2010 and January 2012, 42 cases of elderly patients with non-small cell lung cancer admitted in our hospital were randomly divided into two groups. The treatment group was treated with Gemcitabine, while the control group was treated by Tarceva. The curative effects and incidence of various adverse reactions were compared between two groups. Results After treatment, the effective rate, clinical benefit response rate and 1-year survival rate of treatment group were significantly higher than those of the control group. The incidence rates of leu-kopenia, thrombocytopenia, nausea and vomiting and hepatic dysfunction were significantly lower in the treatment group than in the control group（P〈0.05）. Conclusion Gemcitabine monotherapy was more effective and safe for elderly patients with advanced non-small cell lung cancer than Tarceva, and worthy of clinical popularization.